Martin David Harp

The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the United States.

A University of Chicago-led ASRS 2026 poster explores how large language and vision-language models could help retina specialists manage imaging, records, and clinical trial matching—without replacing physician judgment.

Louie Cai, MD, discusses why manual prescreening is so labor-intensive, how the study was designed, and what broader adoption of AI-assisted screening could mean for clinician time, patient satisfaction, and the pace of drug development.

Carl C. Awh, MD, FASRS, presented 2-year data at ASRS 2026 showing 4D-150 gene therapy cut anti-VEGF injection burden in wet AMD, with strong safety through 4 years of follow-up.

In a first-in-human Phase 1 trial, a single TH103 injection improved vision and reduced fluid in treatment-naive wet AMD, with roughly a third of patients needing no retreatment through 6 months.

Real-world data presented at ASRS 2026 show pegcetacoplan slowed photoreceptor and RPE loss in geographic atrophy, with a greater treatment effect in eyes with concurrent neovascular AMD.

New real-world data from ASRS 2026 show nearly 40% of wet AMD patients go 180+ days without anti-VEGF treatment within a year, and treatment gaps are linked to worse long-term vision.

A real-world Vestrum database analysis found pegcetacoplan was linked to better visual acuity outcomes in geographic atrophy, including in patients with concurrent neovascular AMD, per Nimesh Patel, MD, at ASRS 2026.

Michael Ip, MD, presented a large-scale analysis of OCT biomarkers in diabetic macular edema (DME), drawing on data from the DRCR Retina Network's Protocol T trial.

An AI platform that screens patient charts for clinical trial eligibility increased randomization by 37.5% and cut screen failures by 13% in a retina practice.

Arshad M. Khanani, MD, MA, discusses phase 3 SOL-1 data showing axitinib sustained vision in wet AMD for 9-12 months after 1 dose, outperforming aflibercept 2 mg.